Overview

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Status:
Completed

Trial end date:
2019-05-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborators:

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.